Stephen E. Spurgeon

7.9k total citations · 1 hit paper
98 papers, 2.4k citations indexed

About

Stephen E. Spurgeon is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Stephen E. Spurgeon has authored 98 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Genetics, 50 papers in Pathology and Forensic Medicine and 31 papers in Oncology. Recurrent topics in Stephen E. Spurgeon's work include Chronic Lymphocytic Leukemia Research (72 papers), Lymphoma Diagnosis and Treatment (50 papers) and Immunodeficiency and Autoimmune Disorders (14 papers). Stephen E. Spurgeon is often cited by papers focused on Chronic Lymphocytic Leukemia Research (72 papers), Lymphoma Diagnosis and Treatment (50 papers) and Immunodeficiency and Autoimmune Disorders (14 papers). Stephen E. Spurgeon collaborates with scholars based in United States, Poland and India. Stephen E. Spurgeon's co-authors include Ian W. Flinn, Richard R. Furman, Jennifer R. Brown, Steven Coutré, Brad S. Kahl, Nina D. Wagner‐Johnston, Sissy Peterman, Don M. Benson, Albert S. Yu and John C. Byrd and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Stephen E. Spurgeon

90 papers receiving 2.4k citations

Hit Papers

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
    2014 465 citations Jennifer R. Brown, Stephen E. Spurgeon et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen E. Spurgeon United States 25 1.6k 1.3k 794 690 549 98 2.4k
Thomas E. Boyd United States 22 1.4k 0.9× 1.2k 0.9× 751 0.9× 727 1.1× 555 1.0× 56 2.4k
Ellen Schlette United States 28 1.3k 0.8× 1.3k 1.0× 701 0.9× 700 1.0× 632 1.2× 69 2.3k
Soham D. Puvvada United States 17 1.1k 0.7× 990 0.8× 810 1.0× 1.0k 1.5× 415 0.8× 59 2.6k
Jacqueline C. Barrientos United States 27 2.3k 1.4× 1.9k 1.5× 543 0.7× 630 0.9× 995 1.8× 178 2.9k
Leslie A. Andritsos United States 30 2.1k 1.3× 1.5k 1.1× 967 1.2× 1.0k 1.5× 1.1k 2.0× 161 3.5k
Enrico Tiacci Italy 27 1.1k 0.7× 1.1k 0.8× 1.1k 1.4× 703 1.0× 746 1.4× 77 2.8k
Sarah E. M. Herman United States 19 2.1k 1.3× 1.6k 1.2× 514 0.6× 504 0.7× 1.0k 1.8× 42 2.5k
Kathryn S. Kolibaba United States 22 2.0k 1.2× 2.0k 1.5× 710 0.9× 1.4k 2.0× 642 1.2× 93 3.5k
Lori A. Gressick Australia 10 1.0k 0.7× 772 0.6× 605 0.8× 474 0.7× 349 0.6× 13 1.7k
Paul M. Barr United States 32 2.5k 1.6× 2.6k 2.0× 642 0.8× 1.2k 1.7× 951 1.7× 188 3.9k

Countries citing papers authored by Stephen E. Spurgeon

Since Specialization
Citations

This map shows the geographic impact of Stephen E. Spurgeon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen E. Spurgeon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen E. Spurgeon more than expected).

Fields of papers citing papers by Stephen E. Spurgeon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen E. Spurgeon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen E. Spurgeon. The network helps show where Stephen E. Spurgeon may publish in the future.

Co-authorship network of co-authors of Stephen E. Spurgeon

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen E. Spurgeon. A scholar is included among the top collaborators of Stephen E. Spurgeon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen E. Spurgeon. Stephen E. Spurgeon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gopal, Ajay K., Philippe Armand, Sattva S. Neelapu, et al.. (2025). Nivolumab plus relatlimab for patients with relapsed or progressed B-cell malignancies in RELATIVITY-022. Blood Advances. 9(13). 3383–3394. 1 indexed citations
3.
Torka, Pallawi, Lu Chen, Xiaoguang Wang, et al.. (2023). Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Blood Cancer Journal. 13(1). 9–9. 11 indexed citations
4.
Lyski, Zoë L., Myung Sun Kim, David X. Lee, et al.. (2022). Immunogenicity of Pfizer mRNA COVID-19 Vaccination Followed by J&J Adenovirus COVID-19 Vaccination in Two Patients with Chronic Lymphocytic Leukemia. SHILAP Revista de lepidopterología. 2022. 1–5. 2 indexed citations
5.
6.
Lyski, Zoë L., Myung Sun Kim, David X. Lee, et al.. (2021). Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. Blood Advances. 6(4). 1207–1211. 11 indexed citations
7.
8.
Wang, Michael, Matthew Mei, Paul M. Barr, et al.. (2021). Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma. Blood. 138(Supplement 1). 528–528. 7 indexed citations
9.
Morschhauser, Franck, Martin J.S. Dyer, Harriet S. Walter, et al.. (2020). Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. Leukemia. 35(7). 2108–2113. 13 indexed citations
10.
Spurgeon, Stephen E., Kamal Sharma, David F. Claxton, et al.. (2019). Phase 1–2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B‐cell non‐Hodgkin lymphoma and previously untreated mantle cell lymphoma. British Journal of Haematology. 186(6). 845–854. 19 indexed citations
11.
Lachowiez, Curtis A., Kevin P. White, & Stephen E. Spurgeon. (2018). Exaggerated arthropod assault: Eosinophilic dermatosis in a patient with small lymphocytic lymphoma. Clinical Case Reports. 6(9). 1893–1895. 2 indexed citations
12.
Barr, Paul M., Gene Saylors, Stephen E. Spurgeon, et al.. (2016). Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. Blood. 127(20). 2411–2415. 114 indexed citations
13.
Spurgeon, Stephen E., Brian G. Till, Peter Martin, et al.. (2016). Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. JNCI Journal of the National Cancer Institute. 109(1). djw263–djw263. 10 indexed citations
14.
Gordon, Max J., Paul Tardi, Marc Loriaux, et al.. (2016). CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leukemia Research. 53. 39–49. 22 indexed citations
15.
Soderquist, Ryan S., Sumner Kilmarx, Stephen E. Spurgeon, et al.. (2015). Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS ONE. 10(11). e0143685–e0143685. 31 indexed citations
16.
Geller, Matthew D., et al.. (2014). Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event. Cancer Genetics. 207(7-8). 340–343. 4 indexed citations
17.
Braun, Theodore P., et al.. (2014). Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome. Leukemia Research Reports. 4(1). 8–11. 3 indexed citations
18.
Tyner, Jeffrey, Armand Bankhead, Guang Fan, et al.. (2012). Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening. Cancer Research. 73(1). 285–296. 100 indexed citations
19.
Spurgeon, Stephen E., Greg Coffey, Luke B. Fletcher, et al.. (2012). The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia. Journal of Pharmacology and Experimental Therapeutics. 344(2). 378–387. 40 indexed citations
20.
Gardiner, Stuart K., et al.. (2012). Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007. Leukemia & lymphoma. 53(8). 1488–1493. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas E. Boyd Breakdown of academic impact, for papers by Ellen Schlette Breakdown of academic impact, for papers by Soham D. Puvvada Breakdown of academic impact, for papers by Jacqueline C. Barrientos Breakdown of academic impact, for papers by Leslie A. Andritsos Breakdown of academic impact, for papers by Enrico Tiacci Breakdown of academic impact, for papers by Sarah E. M. Herman Breakdown of academic impact, for papers by Kathryn S. Kolibaba Breakdown of academic impact, for papers by Lori A. Gressick Breakdown of academic impact, for papers by Paul M. Barr
Rankless by CCL
2026